Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OCLN pseudogene 1 (OCLNP1) is a processed pseudogene in humans, related to the parental OCLN gene that encodes the tight junction protein occludin[5][1]. Like other pseudogenes, OCLNP1 does not code for a functional protein and is traditionally considered nonfunctional; however, recent research shows that pseudogenes can play regulatory roles at the RNA level, such as acting as competing endogenous RNAs (ceRNAs) or modulating various gene expression networks[2][4][9]. Despite this, OCLNP1 itself is not a recognized therapeutic target, is not used as a druggable entity, and has no established role as a biomarker or in disease beyond its potential as a noncoding regulatory element in cellular networks[5][9]. There are no known drugs or safety concerns associated with OCLNP1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on OCLN pseudogene 1 (OCLNP1).